Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
3,367,000
-
Total 13F shares
-
373,392
-
Share change
-
-8,681
-
Total reported value
-
$931,696
-
Price per share
-
$2.50
-
Number of holders
-
18
-
Value change
-
-$29,342
-
Number of buys
-
2
-
Number of sells
-
3
Institutional Holders of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) as of Q1 2025
As of 31 Mar 2025,
Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
373,392 shares.
The largest 10 holders included
TYNDALL CAPITAL PARTNERS L P, Siren, L.L.C., GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, BlackRock, Inc., UBS Group AG, FMR LLC, Tower Research Capital LLC (TRC), MORGAN STANLEY, and GROUP ONE TRADING LLC.
This page lists
18
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.